COX CARRIE SMITH — SEC Form 4 filings
SEC reporting owner CIK 1110753. 15 Form 4 filings on record with FilingPulse; latest filed 2026-05-18.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-29 to 2026-05-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 77,869 shares, $602,347 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 8,838 shares, $2,708,029 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: sale of 8,393 shares @ $306.37 ($2,571,394) in TEXAS INSTRUMENTS INC, filed 2026-05-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| TEXAS INSTRUMENTS INC (TXN) | Director | 4 | — | 2 legs · 8,838 sh · $2,708,029 | 10 |
| Organon & Co. (OGN) | Executive Chair, Director | 4 | 2 legs · 77,869 sh · $602,347 | — | 2 |
| Solventum Corp (SOLV) | Director | 6 | — | — | 10 |
| Cartesian Therapeutics, Inc. (RNAC) | Director | 1 | — | — | 2 |
Form 4 filings — COX CARRIE SMITH
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-18 | 4 | Solventum Corp (SOLV) | Grant/award (A): 4,848 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | TEXAS INSTRUMENTS INC (TXN) | Option exercise (M): 4,306 @ $110.15 · Option exercise (M): 4,532 @ $104.41 · Sale (S): 8,393 @ $306.37 · Sale (S): 445 @ $307.04 · Option exercise (M): 4,306 (derivative) @ $0 · Option exercise (M): 4,532 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Solventum Corp (SOLV) | Option exercise (M): 4,916 @ $0 · Option exercise (M): 4,916 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | Solventum Corp (SOLV) | Option exercise (M): 6,336 @ $0 · Option exercise (M): 6,336 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | TEXAS INSTRUMENTS INC (TXN) | Grant/award (A): 525 @ $0 · Grant/award (A): 1,860 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Organon & Co. (OGN) | Purchase (P): 65,400 @ $7.67 | EDGAR |
| 2025-06-16 | 4 | Organon & Co. (OGN) | Grant/award (A): 23,904.38 (derivative) @ $10.04 | EDGAR |
| 2025-05-15 | 4 | Solventum Corp (SOLV) | Option exercise (M): 5,148 @ $0 · Option exercise (M): 5,148 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Organon & Co. (OGN) | Purchase (P): 12,469 @ $8.07 | EDGAR |
| 2025-05-02 | 4 | Solventum Corp (SOLV) | Grant/award (A): 4,916 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | TEXAS INSTRUMENTS INC (TXN) | Grant/award (A): 614 @ $0 · Grant/award (A): 2,551 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Cartesian Therapeutics, Inc. (RNAC) | Grant/award (A): 2,600 @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Organon & Co. (OGN) | Grant/award (A): 9,638.55 (derivative) @ $20.75 | EDGAR |
| 2024-05-15 | 4 | Solventum Corp (SOLV) | Grant/award (A): 5,148 (derivative) @ $0 · Grant/award (A): 6,336 (derivative) @ $0 | EDGAR |
| 2024-01-29 | 4 | TEXAS INSTRUMENTS INC (TXN) | Grant/award (A): 686 @ $0 · Grant/award (A): 3,066 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1110753 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →